A multicenter clinical trial led by UC Davis Health found that a novel monoclonal antibody, nebokitug, was safe and showed potential effectiveness in patients with primary sclerosing cholangitis (PSC), a rare but progressive liver disease. Early results suggest reduced inflammation and fibrosis, offering hope for a condition with limited treatment options.
